The historical rank and industry rank for Maternus-Kliniken AG's ROE % or its related term are showing as below:
HAM:MAK's ROE % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 5.72 * Ranked among companies with meaningful ROE % only.
Maternus-Kliniken AG (HAM:MAK) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Maternus-Kliniken AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maternus-Kliniken AG ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Maternus-Kliniken AG's ROE % distribution charts can be found below:
* The bar in red indicates where Maternus-Kliniken AG's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.
Maternus-Kliniken AG (HAM:MAK) has a ROE % of 0.00% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Maternus-Kliniken AG and its competitors. According to the industry distribution chart, Maternus-Kliniken AG ranks #999999 out of 628 companies in the Healthcare Providers & Services industry.
Is Maternus-Kliniken AG's ROE % too high?
Maternus-Kliniken AG's current ROE % is 0.00%. Based on the distribution chart, Maternus-Kliniken AG ranks #999999 out of 628 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Maternus-Kliniken AG has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Maternus-Kliniken AG's ROE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Maternus-Kliniken AG ranks #999999 out of 628 companies for ROE %. This places Maternus-Kliniken AG in the lower half of its industry. The industry median ROE % is 5.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.72, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Maternus-Kliniken AG and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maternus-Kliniken AG's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maternus-Kliniken AG stock overvalued right now?
Based on GuruFocus' analysis, Maternus-Kliniken AG (HAM:MAK) is currently considered Possible Value Trap. The stock's GF Value™ is €1.72, compared to a current price of €0.92 — trading 46.5% below its estimated fair value. The current ROE % is 0.00%. Maternus-Kliniken AG's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Maternus-Kliniken AG (HAM:MAK), the current ROE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maternus-Kliniken AG (HAM:MAK) Overvalued in 2026?
Based on GuruFocus' analysis, Maternus-Kliniken AG stock appears to be undervalued.
The current stock price of €0.92 is trading 46.5% below its estimated GF Value™ of €1.72.
GuruFocus considers Maternus-Kliniken AG to be Possible Value Trap.
Key valuation signals for HAM:MAK:
ROE %: 0.00%
GF Value™: €1.72 vs. price of €0.92 (46.5% below fair value)
No single metric tells the full story. See the HAM:MAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:MAK has been successfully added to your 
